This work was funded by the Wellcome (095101 [ALG], 200837 [ALG], 098381 [MIM], 106130 [ALG, MIM], 203141 (ALG, MIM], 203141 [MIM]), Medical Research Council (MR/L020149/1) [MIM, ALG, FK, ATH], European Union Horizon 2020 Programme (T2D Systems) [ALG, TH], and NIH (U01-DK105535
However, the lack of long-term human clinical data means some uncertainty remains
not a fan of any supplements with GMO soy or corn or multi-level retailers
10.1007/s11064-015-1540-2 75 ShivakumarB
GLP-1RAs linked to fewer major limb events The meta-analysis of 12 studies found that GLP-1RA use was associated with a 27% lower risk of major limb events in patients with type 2 diabetes and PAD compared with placebo, other glucose-lowering therapies, including SGLT-2 inhibitors and DPP-4 inhibitors, or GLP-1RA non-use
Research Protocol Considerations Understanding GHK-Cus biological activity requires careful attention to the concentration ranges, delivery methods, and model systems used in preclinical research
